(RNA)ctive® Cancer Immunotherapies and Prophylactic Vaccines
RNActive® molecules are being developed as immunotherapeutics for the treatment of cancer and as prophylactic vaccines against infectious diseases.
RNActive® molecules are being developed as immunotherapeutics for the treatment of cancer and as prophylactic vaccines against infectious diseases.
By modifying the sequence of mRNA, the stability of the molecule is improved while translational levels are enhanced without changing the amino acid sequence of the corresponding protein. The immunogenicity of the molecule is increased by complexation with protamine.
RNActive® vaccines have self-adjuvanting properties and allow for a robust expression of the antigenic target protein, while simultaneously providing a strong danger signal leading to activation of different pattern recognition receptors (e.g. TLR7, TLR8). In this way they stimulate the adaptive and innate immune systems, leading to a balanced humoral and T-cell-mediated immune response that includes antibody-producing B-lymphocytes, cytotoxic T-cells, memory T-cells and helper T-cells.
*in preclinical models
RNActive® cancer immunotherapies have demonstrated favorable safety profiles and immunogenicity in clinical trials for prostate cancer and lung cancer, inducing a balanced humoral and T-cell immune response.
In the field of prophylactic vaccines for infectious diseases, RNActive® vaccines have shown very promising preclinical and also first clinical data.